The main objective of this trial is to evaluate the effect of Semaglutide on the burden of
coronary atherosclerosis, based on the change in Percent Atheroma Volume (PAV) by quantifying
atheroma plaque throughout the coronary tree based on the analysis of CCTA in asymptomatic
subjects with T2D in optimized and stable treatment with Semaglutide.
Phase:
Phase 3
Details
Lead Sponsor:
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León